635 related articles for article (PubMed ID: 16180014)
1. Anti-DNA topoisomerase II alpha autoantibodies in Japanese patients with systemic sclerosis.
Hayakawa I; Hasegawa M; Takehara K; Sato S
Arch Dermatol Res; 2005 Oct; 297(4):180-3. PubMed ID: 16180014
[TBL] [Abstract][Full Text] [Related]
2. Decreased levels of autoantibody against histone deacetylase 3 in patients with systemic sclerosis.
Kuwatsuka Y; Ogawa F; Iwata Y; Komura K; Muroi E; Hara T; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
Autoimmunity; 2009 Feb; 42(2):120-5. PubMed ID: 19021012
[TBL] [Abstract][Full Text] [Related]
3. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma.
Hayakawa I; Hasegawa M; Takehara K; Sato S
Arthritis Rheum; 2004 Jan; 50(1):227-32. PubMed ID: 14730620
[TBL] [Abstract][Full Text] [Related]
4. Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis.
Mimura Y; Ihn H; Jinnin M; Asano Y; Yamane K; Yazawa N; Tamaki K
Br J Dermatol; 2004 Oct; 151(4):803-8. PubMed ID: 15491420
[TBL] [Abstract][Full Text] [Related]
5. IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients.
García de la Peña-Lefebvre P; Chanseaud Y; Tamby MC; Reinbolt J; Batteux F; Allanore Y; Kahan A; Meyer O; Benveniste O; Boyer O; Guillevin L; Boissier MC; Mouthon L
Clin Immunol; 2004 Jun; 111(3):241-51. PubMed ID: 15183145
[TBL] [Abstract][Full Text] [Related]
6. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis.
Kim D; Peck A; Santer D; Patole P; Schwartz SM; Molitor JA; Arnett FC; Elkon KB
Arthritis Rheum; 2008 Jul; 58(7):2163-73. PubMed ID: 18576347
[TBL] [Abstract][Full Text] [Related]
7. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis.
Hénault J; Tremblay M; Clément I; Raymond Y; Senécal JL
Arthritis Rheum; 2004 Oct; 50(10):3265-74. PubMed ID: 15476238
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies against phosphatidylserine-prothrombin complex in patients with systemic sclerosis.
Hasegawa M; Sato S; Yanaba K; Komura K; Yamazaki M; Takehara K
Ann Rheum Dis; 2004 Nov; 63(11):1514-7. PubMed ID: 15479907
[TBL] [Abstract][Full Text] [Related]
9. Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress.
Iwata Y; Ogawa F; Komura K; Muroi E; Hara T; Shimizu K; Hasegawa M; Fujimoto M; Tomita Y; Sato S
Rheumatology (Oxford); 2007 May; 46(5):790-5. PubMed ID: 17309887
[TBL] [Abstract][Full Text] [Related]
10. Anti-agalactosyl IgG antibodies in sera from patients with systemic sclerosis.
Nishijima C; Sato S; Takehara K
J Rheumatol; 2001 Aug; 28(8):1847-51. PubMed ID: 11508588
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies against calpastatin in sera from patients with systemic sclerosis.
Sato S; Hasegawa M; Nagaoka T; Takamatsu Y; Yazawa N; Ihn H; Kikuchi K; Takehara K
J Rheumatol; 1998 Nov; 25(11):2135-9. PubMed ID: 9818655
[TBL] [Abstract][Full Text] [Related]
12. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis.
Hu PQ; Fertig N; Medsger TA; Wright TM
Arthritis Rheum; 2003 May; 48(5):1363-73. PubMed ID: 12746909
[TBL] [Abstract][Full Text] [Related]
13. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis.
Hara T; Ogawa F; Muroi E; Komura K; Takenaka M; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2008 Mar; 35(3):451-7. PubMed ID: 18203319
[TBL] [Abstract][Full Text] [Related]
14. Autoantibodies against matrix metalloproteinase-1 in patients with localized scleroderma.
Tomimura S; Ogawa F; Iwata Y; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
J Dermatol Sci; 2008 Oct; 52(1):47-54. PubMed ID: 18565735
[TBL] [Abstract][Full Text] [Related]
15. Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations.
Kodera M; Hayakawa I; Komura K; Yanaba K; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2005 Apr; 32(4):629-36. PubMed ID: 15801017
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
Yamane K; Ihn H; Kubo M; Yazawa N; Kikuchi K; Soma Y; Tamaki K
J Rheumatol; 2000 Apr; 27(4):930-4. PubMed ID: 10782818
[TBL] [Abstract][Full Text] [Related]
17. An immunodominant epitope on DNA topoisomerase I is conformational in nature: heterogeneity in its recognition by systemic sclerosis sera.
Kuwana M; Kaburaki J; Medsger TA; Wright TM
Arthritis Rheum; 1999 Jun; 42(6):1179-88. PubMed ID: 10366110
[TBL] [Abstract][Full Text] [Related]
18. Association of HLA class II genes with systemic sclerosis in Koreans.
Kang SH; Park MH; Song EY; Kang SJ; Lee EB; Song YW; Takeuchi F
J Rheumatol; 2001 Jul; 28(7):1577-83. PubMed ID: 11469465
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis.
Kuwana M; Kaburaki J; Mimori T; Kawakami Y; Tojo T
Arthritis Rheum; 2000 May; 43(5):1074-84. PubMed ID: 10817562
[TBL] [Abstract][Full Text] [Related]
20. OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement.
Lopez LR; Simpson DF; Hurley BL; Matsuura E
Ann N Y Acad Sci; 2005 Jun; 1051():313-22. PubMed ID: 16126973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
